Bambi Grilley

Houston Methodist — United States

Medicine · Health Sciences

35h-index10.1kcitations128works21.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(97), Virus-based gene therapy research(37), Immune Cell Function and Interaction(25), Immunotherapy and Immune Responses(24), Cytomegalovirus and herpesvirus research(19)

Publications128 total

CLL-1 chimeric antigen receptor T-cells for the treatment of Acute Myeloid Leukemia: A phase 1 clinical trial
Blood·2025
Autologous multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma (PDAC): results of a Phase I, three-arm, nonrandomized clinical trial (TACTOPS)
immuneACCESS·2025
Rewriting the code: examining the promise and responsibility of gene editing
Cell and Gene Therapy Insights·2025
How to democratize cell and gene therapy: A global approach
Molecular Therapy·2025· 7 cited
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma
Nature Medicine·2025· 36 cited
International Society for Cell & Gene Therapy Expanded Access Working Group position paper: key considerations to support equitable and ethical expanded access to investigational cell- and gene-based interventions
Cytotherapy·2025· 4 citedOpen Access
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Carolina Digital Repository (University of North Carolina at Chapel Hill)·2024· 6 citedOpen Access
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Nature·2024· 155 citedOpen Access
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial
UNC Libraries·2024· 1 citedOpen Access
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
UNC Libraries·2024Open Access
Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST for treatment of advanced HER2-positive solid tumors (VISTA).
Journal of Clinical Oncology·2024· 8 cited
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors
Journal of Clinical Oncology·2024· 53 citedOpen Access
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies
Transplantation and Cellular Therapy·2024· 5 citedOpen Access
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
UNC Libraries·2024Open Access
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial
Nature Cancer·2024· 65 citedOpen Access
Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for Neuroblastoma
2024· 4 citedOpen Access
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers
2024· 15 citedOpen Access
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study
The Lancet Oncology·2024· 54 citedOpen Access
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
Nature Medicine·2024Open Access
Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy
Cytotherapy·2023· 8 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Helen E. Heslop(43), Malcolm K. Brenner(43), Adrian P. Gee(33), Cliona M. Rooney(32), Gianpietro Dotti(22), Carlos A. Ramos(18), Hao Liu(16), Olga Dakhova(16), Zhuyong Mei(15), Huimin Zhang(15), Tao Wang(15), Barbara Savoldo(14), Stephen Gottschalk(13), Robert A. Krance(12), Premal Lulla(12), Birju Mehta(11), Catherine Robertson(10), Ann M. Leen(10), Meng-Fen Wu(10), Rammurti T. Kamble(9)